Journal Watch · Clinical Pharmacology & Therapeutics · 2026

Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.

We showed that preemptive PGx testing can be successfully implemented in a German hospital with high acceptance among physicians and GPs, and that PGx integration into the EHR supports broader adoption in precision medicine.

Tremmel R, Schreeck F, Jaeger S et al.Clinical Pharmacology & Therapeutics3 min readPharma relevance 75/100

DOI: 10.1002/cpt.70083PMID: 41074844Study type: clinical study

TL;DR

We showed that preemptive PGx testing can be successfully implemented in a German hospital with high acceptance among physicians and GPs, and that PGx integration into the EHR supports broader adoption in precision medicine.

Key findings

  • GPs maintained optimized treatment in 77% of those patients with a medication change initiated during hospitalization.
  • One in 10 patients discussed results with their GPs.
  • GPs favored PGx for future prescriptions and requested training.
  • We showed that preemptive PGx testing can be successfully implemented in a German hospital with high acceptance among physicians and GPs, and that PGx integration into the EHR supports broader adoption in precision medicine.

Numbers at a glance (from the abstract)

95%21.5%75.5%21%77%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

CPIC/DPWG guideline-based PGx reports were integrated into the EHR system and provided as a mobile and web application for patients through a genetic information system. Medication profiles and questionnaires evaluated PGx-based decisions 3 months post-discharge. Among 255 patients, 95% had at least one actionable PGx variant, most commonly affecting statins, 5-fluorouracil, irinotecan, and pantoprazole. Actionable recommendations were provided in 21.5%, with hospital physicians modifying treatment subsequently in 75.5%. We identified 57 clinically significant DDIs, including PGx drugs in 21%.

Full abstract (original)

Background: Pharmacogenomics (PGx) helps to explain variability in drug response, including adverse drug reactions. Functional variants in genes affecting drug absorption, distribution, metabolism, and excretion (ADME) have been described. Despite PGx guidelines (e.g., CPIC and DPWG) enabling genotype-guided drug and dose selection, preemptive implementation remains challenging due to various issues including standardized result communication and integration into electronic health record (EHR) systems. We implemented PGx testing as well as drug-drug interaction (DDI) screening in a German academic hospital and assessed their impact on physicians, general practitioners (GPs), and patients. A novel PGx workflow was established using a 60-genetic variant panel.

What they did: CPIC/DPWG guideline-based PGx reports were integrated into the EHR system and provided as a mobile and web application for patients through a genetic information system. Medication profiles and questionnaires evaluated PGx-based decisions 3 months post-discharge. Among 255 patients, 95% had at least one actionable PGx variant, most commonly affecting statins, 5-fluorouracil, irinotecan, and pantoprazole. Actionable recommendations were provided in 21.5%, with hospital physicians modifying treatment subsequently in 75.5%. We identified 57 clinically significant DDIs, including PGx drugs in 21%.

Results & conclusions: GPs maintained optimized treatment in 77% of those patients with a medication change initiated during hospitalization. One in 10 patients discussed results with their GPs. GPs favored PGx for future prescriptions and requested training. We showed that preemptive PGx testing can be successfully implemented in a German hospital with high acceptance among physicians and GPs, and that PGx integration into the EHR supports broader adoption in precision medicine.

Abstract © the authors / Clinical Pharmacology & Therapeutics (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1002/cpt.70083 · PubMed 41074844.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Clinical Pharmacology & Therapeutics for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Clinical Pharmacology & Therapeutics study find?

We showed that preemptive PGx testing can be successfully implemented in a German hospital with high acceptance among physicians and GPs, and that PGx integration into the EHR supports broader adoption in precision medicine.

What type of study is this?

It is a clinical study, published in Clinical Pharmacology & Therapeutics in 2026. CPIC/DPWG guideline-based PGx reports were integrated into the EHR system and provided as a mobile and web application for patients through a genetic information system.

Where can I read the original paper?

The original is at the publisher via DOI 10.1002/cpt.70083. PubMed ID: 41074844. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Tremmel R, Schreeck F, Jaeger S et al.. Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.. Clinical Pharmacology & Therapeutics (2026). DOI: 10.1002/cpt.70083.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/clinical-implementation-of-pharmacogenomics-and-drug-drug-interaction-sc-t70083/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides